by | May 7, 2024 | Publications
Cell Commun Signal. 2024 May 6;22(1):258. doi: 10.1186/s12964-024-01628-4. ABSTRACT Although bortezomib (BTZ) is the cornerstone of anti-multiple myeloma (MM) therapy, the inevitable primary and secondary drug resistance still seriously affects the prognosis of...
by | May 6, 2024 | Publications
Clin Case Rep. 2024 May 2;12(5):e8890. doi: 10.1002/ccr3.8890. eCollection 2024 May. ABSTRACT The coexistence of extramedullary hematopoiesis and extramedullary multiple myeloma can occur and present as painful pelvic masses. In such a case, normal hematopoietic cells...
by | May 6, 2024 | Publications
Clin Cosmet Investig Dermatol. 2024 Apr 27;17:941-951. doi: 10.2147/CCID.S464039. eCollection 2024. ABSTRACT We report a fatal case of disseminated herpes zoster in a patient with multiple myeloma, illustrating the severe risks immunocompromised individuals face from...
by | May 6, 2024 | Publications
Cancer Diagn Progn. 2024 May 3;4(3):288-294. doi: 10.21873/cdp.10322. eCollection 2024 May-Jun. ABSTRACT BACKGROUND/AIM: Multiple myeloma (MM) is a hematological malignancy that arises when plasma cells undergo malignant monoclonal proliferation. This study aimed to...
by | May 6, 2024 | Publications
Leuk Res Rep. 2024 Apr 18;21:100460. doi: 10.1016/j.lrr.2024.100460. eCollection 2024. ABSTRACT Orbital plasmacytoma is rare and has only been reported in the context of the initial diagnosis of multiple myeloma. Moreover, isolated orbital plasmacytoma without any...
by | May 6, 2024 | Publications
Indian J Hematol Blood Transfus. 2024 Apr;40(2):246-254. doi: 10.1007/s12288-023-01701-x. Epub 2023 Oct 25. ABSTRACT Renal dysfunction is a common complication of MM and is associated with poor prognosis, particularly when progressive. Early identification of renal...
